Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-11

Study Completion Date

2016-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bupivacaine spinal is commonly performed as the primary anesthetic for orthopedic procedures. In some cases the duration of the block is inadequate. An epinephrine wash is sometimes performed to prolong the duration of the block. The epinephrine wash may prolong the duration of the block, and if it does, to what extent?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Bupivacaine Dose Sparing Effect of Intrathecal Epinephrine

NCT01261078

Spinal Anesthesia

COMPLETED NA

Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization

NCT02368054

Cervical Intraepithelial Neoplasia

COMPLETED PHASE4

0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka

NCT03303794

Anesthesia

TERMINATED PHASE3

Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia

NCT02654860

Phase 1: Pain Management Phase 2: Pain Management

COMPLETED PHASE1/PHASE2

ED50 of Dexmedetomidine as an Adjuvant to 0.5% Hyperbaric Bupivacaine 12.5 mg for Spinal Anesthesia in Hip and Knee Surgery: An Up-and-Down Method Approach

NCT07144215

Knee Surgery Pelvic Surgery Spinal Aneshtesia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthropathy of Hip Arthropathy of Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bupivacaine Only

The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.

Group Type PLACEBO_COMPARATOR

Bupivacaine Only

Intervention Type DRUG

The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.

EPI25 group

The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.

Group Type ACTIVE_COMPARATOR

EPI25

Intervention Type DRUG

The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.

EPI50 group

The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.

Group Type ACTIVE_COMPARATOR

EPI50 group

Intervention Type DRUG

The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc

EPI75 group

The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.

Group Type ACTIVE_COMPARATOR

EPI75 group

Intervention Type DRUG

The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.

EPI100 group

The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc

Group Type ACTIVE_COMPARATOR

EPI100 group

Intervention Type DRUG

The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine Only

The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.

Intervention Type DRUG

EPI25

The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.

Intervention Type DRUG

EPI50 group

The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc

Intervention Type DRUG

EPI75 group

The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.

Intervention Type DRUG

EPI100 group

The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* Patients scheduled for total hip or knee replacement

Exclusion Criteria

* Patients taking anticoagulation
* Infection at or near the intended needle insertion site
* Patients with sacral decubitus ulcer at or near the intended needle insertion site aortic stenosis
* Complex spine anatomy
* ASA class greater than III
* Failed SAB as determined by the staff anesthesiologist

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes